The Breast
Volume 19, Issue 1 , Pages 33-37 , February 2010

Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report

  • E. Munzone

      Affiliations

    • Division of Medical Oncology, European Institute of Oncology, via Ripamonti, 435, 20141 Milan, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 02 57489405; fax: +39 02 57489457.
    • ,
  • A. Di Pietro

      Affiliations

    • Division of Medical Oncology, European Institute of Oncology, via Ripamonti, 435, 20141 Milan, Italy
    • ,
  • A. Goldhirsch

      Affiliations

    • Division of Medical Oncology, European Institute of Oncology, via Ripamonti, 435, 20141 Milan, Italy
    • ,
  • I. Minchella

      Affiliations

    • Division of Medical Oncology, European Institute of Oncology, via Ripamonti, 435, 20141 Milan, Italy
    • ,
  • E. Verri

      Affiliations

    • Division of Medical Oncology, European Institute of Oncology, via Ripamonti, 435, 20141 Milan, Italy
    • ,
  • M. Cossu Rocca

      Affiliations

    • Division of Medical Oncology, European Institute of Oncology, via Ripamonti, 435, 20141 Milan, Italy
    • ,
  • C. Marenghi

      Affiliations

    • Division of Medical Oncology, European Institute of Oncology, via Ripamonti, 435, 20141 Milan, Italy
    • ,
  • G. Curigliano

      Affiliations

    • Division of Medical Oncology, European Institute of Oncology, via Ripamonti, 435, 20141 Milan, Italy
    • ,
  • D. Radice

      Affiliations

    • Division of Epidemiology and Biostatistics, European Institute of Oncology, via Ripamonti, 435, 20141 Milan, Italy
    • ,
  • L. Adamoli

      Affiliations

    • Division of Medical Oncology, European Institute of Oncology, via Ripamonti, 435, 20141 Milan, Italy
    • ,
  • F. Nolè

      Affiliations

    • Division of Medical Oncology, European Institute of Oncology, via Ripamonti, 435, 20141 Milan, Italy

Received 5 June 2009 ,Revised 2 October 2009 ,Accepted 6 October 2009.

References 

  1. Mayer E, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007 Apr;21(2):257–272
  2. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–436
  3. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60(7):1878–1886
  4. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62:6938–6943
  5. Miller K, Sweeney C, Sledge G. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001;19:1195–1206
  6. Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs. 2006 Sep;17(8):961–967
  7. Orlando L, Cardillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer. 2006 Sep 15;6:225
  8. Dellapasqua S, Bertolini F, Bagnardi V, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol. 2008 Oct 20;26(30):4899–4905
  9. O'Brien ME. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs. 2008 Jan;19(1):1–7
  10. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 2002;4(3):95–99
  11. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol. 1996 Jan;36(1):55–63
  12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205–216
  13. Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol. 1998 Jul;9(7):711–716
  14. Goebel FD, Goldstein D, Goos M, et al. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Br J Cancer. 1996 Apr;73(8):989–994
  15. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998 Jul;16(7):2445–2451
  16. Cooley T, Henry D, Tonda M, et al. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist. 2007 Jan;12(1):114–123
  17. Sehouli J, Oskay-Ozcelik G, Kühne J, et al., Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO)  Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol. 2006 Jun;17(6):957–961
  18. Tas F, Guney N, Derin D, Aydiner A, Topuz E. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer. Int J Clin Oncol. 2008 Apr;13(2):156–160
  19. Strauss HG, Hemsen A, Karbe I, et al. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Anticancer Drugs. 2008 Jun;19(5):541–545
  20. Charrois GRJ, Allen TM. Multiple injections of Pegylated Liposomal Doxorubicin: pharmacokinetics and therapeutic activity. JPET. 2003;306:1058–1067
  21. Ranson MR, Carmichael J, O'Byrne K, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol. 1997 Oct;15(10):3185–3191
  22. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer. 2000 Sep 1;89(5):1037–1047
  23. Al-Batran SE, Bischoff J, von Minckwitz G, et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer. 2006 Jun 5;94(11):1615–1620
  24. Al-Batran SE, Meerpohl HG, von Minckwitz G, et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 2006;70(2):141–146
  25. Rivera E, Valero V, Esteva FJ, et al. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother Pharmacol. 2002 Apr;49(4):299–302
  26. Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004 Oct 1;22(19):3893–3901
  27. Alba E, Ruiz-Borrego M, Martín M, et al. Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study. J Clin Oncol. 2007;ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007: 1007
  28. Verma S, Dent S, Chow BJ, Rayson D, Safra T. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev. 2008 Aug;34(5):391–406

PII: S0960-9776(09)00119-2

doi: 10.1016/j.breast.2009.10.003

The Breast
Volume 19, Issue 1 , Pages 33-37 , February 2010

Article Tools

* Image Usage & Resolution